Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Announces Positive Feedback from Health Canada for Ifenprodil COVID-19 Phase 2 Human Trial

GlobeNewswire April 8, 2020

Algernon Finalizes Plan for Human COVID-19 Treatment Tests

Stockhouse Editorial April 3, 2020

Algernon Provides Update on Phase 2 Human Testing of Ifenprodil for COVID-19

GlobeNewswire April 2, 2020

Algernon Submits Chronic Cough Drug for Ethics Approval

Stockhouse Editorial March 30, 2020

Algernon Submits for Ethics Approval for Phase 2 IPF and Chronic Cough Study

GlobeNewswire March 30, 2020

Algernon Provides an Overview of its NP-120 (Ifenprodil) Program for COVID-19

GlobeNewswire March 24, 2020

The Top Healthcare Bullboards: Jan - Mar 2020

Stockhouse Editorial March 23, 2020

Algernon Appoints U.S. Company for cGMP Manufacturing of NP-120 (Ifenprodil) for COVID-19 Clinical Trials

GlobeNewswire March 23, 2020

IIROC Trade Resumption - AGN

Canada NewsWire March 20, 2020

IIROC Trading Halt - AGN

Canada NewsWire March 20, 2020

Algernon Appoints Novotech as CRO For Phase 2 Coronavirus Ifenprodil Trial

GlobeNewswire March 20, 2020

Algernon to Support Planned Phase 2 Trial of Ifenprodil for Coronavirus

GlobeNewswire March 19, 2020

Algernon Contacts Gates Foundation Regarding Funding for New Coronavirus Treatments

GlobeNewswire March 13, 2020

Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency Use

GlobeNewswire March 13, 2020

Algernon Announces Exercise of Warrants and Broker Warrants

GlobeNewswire March 11, 2020

Algernon Announces Coronavirus Update Featured on BioPub Hosted by Dr. KSS MD PhD

GlobeNewswire March 10, 2020

Algernon Scales up Manufacturing of NP-120 (Ifenprodil) to Prepare for Coronavirus and Acute Lung Injury US Clinical Trials

GlobeNewswire March 9, 2020

IIROC Trade Resumption - AGN

Canada NewsWire March 6, 2020

IIROC Trading Halt - AGN

Canada NewsWire March 6, 2020

Algernon Announces Availability of its NP-120 Ifenprodil Drug for Compassionate Use for Coronavirus

GlobeNewswire March 6, 2020